150 related articles for article (PubMed ID: 31569615)
21. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
23. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
24. Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.
Tsolaki V; Zarogiannis S; Zygoulis P; Kalomenidis I; Jagirdar R; Makris D; Daniil Z; Magkouta S; Triantafyllou I; Papanikolaou J; Gourgoulianis KI; Zakynthinos E
Respirology; 2020 Oct; 25(10):1060-1065. PubMed ID: 32124515
[TBL] [Abstract][Full Text] [Related]
25. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Zhang W; Wu X; Wu L; Zhang W; Zhao X
Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
27. Malignant pleural mesothelioma.
Chen SE; Pace MB
Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
[TBL] [Abstract][Full Text] [Related]
28. Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids.
Gendre DAJ; Ameti E; Karenovics W; Perriraz-Mayer N; Triponez F; Serre-Beinier V
Oncotarget; 2021 Nov; 12(24):2375-2387. PubMed ID: 34853659
[TBL] [Abstract][Full Text] [Related]
29. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.
Goudar RK
Ther Clin Risk Manag; 2008 Feb; 4(1):205-11. PubMed ID: 18728709
[TBL] [Abstract][Full Text] [Related]
30. Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ
Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
32. Forchlorfenuron and Novel Analogs Cause Cytotoxic Effects in Untreated and Cisplatin-Resistant Malignant Mesothelioma-Derived Cells.
Henzi T; Diep KL; Oberson A; Salicio V; Bochet CG; Schwaller B
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409322
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
35. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
36. Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
Kanai O; Fujita K; Nakatani K; Mio T
Respirol Case Rep; 2016 Mar; 4(1):28-31. PubMed ID: 26839699
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
Cinausero M; Rihawi K; Sperandi F; Melotti B; Ardizzoni A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S304-S310. PubMed ID: 29507800
[TBL] [Abstract][Full Text] [Related]
38. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Walter RFH; Sydow SR; Berg E; Kollmeier J; Christoph DC; Christoph S; Eberhardt WEE; Mairinger T; Wohlschlaeger J; Schmid KW; Mairinger FD
Cancer Manag Res; 2019; 11():8711-8720. PubMed ID: 31576173
[TBL] [Abstract][Full Text] [Related]
40. Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells.
Gultekin KE; Yurdakonar MK; Yaman E; Yuce US; Yilmaz A; Alp E; Celik A; Demiroz SM; Onen HI
Genet Mol Res; 2013 Nov; 12(4):5405-13. PubMed ID: 24301913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
